EGA
CYTK icon

Eagle Global Advisors’s Cytokinetics CYTK Stock Holding History

Eagle Global Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-27,230
Closed -$285K – 374
2015
Q4 		$285K Sell
27,230
-6,810
-20% -$66.8K 0.01% 284
2015
Q3 		$228K Sell
34,040
-42,570
-56% -$291K 0.01% 309
2015
Q2 		$515K Buy
76,610
+49,450
+182% +$324K 0.01% 202
2015
Q1 		$184K Buy
+27,160
New +$203K ﹤0.01% 320

Other funds holding CYTK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Eagle Global Advisors's CYTK Position: Q1 2016 in Review

Eagle Global Advisors sold out of Cytokinetics (CYTK) in Q1 2016, closing a stake of 27,230 shares — an estimated $285K sold.

Eagle Global Advisors first reported a position in CYTK in Q1 2015 and held it in 4 quarters. The position peaked at $515K in Q2 2015. 109 funds tracked by Wall St. Rank hold CYTK as of Q1 2016.

  • Eagle Global Advisors reported no remaining Cytokinetics position as of Q1 2016 after selling out during the quarter.
  • Eagle Global Advisors sold 27,230 Cytokinetics shares in Q1 2016, an estimated $285K.
  • Eagle Global Advisors first reported a position in Cytokinetics in Q1 2015 and held it in 4 quarters.
  • Eagle Global Advisors's Cytokinetics position peaked at $515K in Q2 2015.
  • 109 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2016.

Based on Eagle Global Advisors's 13F filing for Q1 2016, filed 16 May 2016.